OVERVIEW

Hypertrophic cardiomyopathy (HCM) is one of the most challenging diseases encountered in cardiology practice because of the diversity of its expression and its unpredictable clinical course. In the last two decades, HCM care has seen the development of highly effective interventions that prevent sudden death, relieve symptoms, and prevent stroke. The lecturers at this course are national and international thought leaders in the realm of HCM care. They will discuss the latest medical, electrophysiologic, and surgical advances including: novel pharmacologic therapy of symptoms with myosin ATP-ase inhibition, indications for ICD implantation, and judgements for when an IV-ICD or S-ICD might be chosen, the crucial role of anticoagulation for AFib, and when AF ablation might be indicated. The effect of obesity on HCM phenotype will be discussed.

This webinar will feature a unique nested surgical symposium featuring the world’s foremost myectomy surgeons demonstrating and debating optimal operative techniques. Video of extended myectomy and novel ancillary surgical approaches to the mitral valve will be demonstrated. Evolving research for non-obstructive HCM and indications for cardiac transplantation will be discussed. Current echocardiographic and MRI diagnosis will be covered including how to recognize and quantify the contribution of the mitral valve to obstruction, differentiate between the various hypertrophic heart diseases, as well as TEE planning and monitoring of myectomy. Practical family counseling, non-invasive screening, and genotype analysis will be covered. Recent research concerning the etiology of apical aneurysms in HCM will be discussed. Distinctive obstructive HCM anatomy and physiology are present in up to a third of patients with acute LV ballooning. Differentiation of the cause LV ballooning between obstructive HCM and Takotsubo syndrome will be presented. 

LEARNING OBJECTIVES

After participating in this activity, clinicians should be able to:

1. Appreciate how the phenotype determines treatment protocols
2. Recognize that the phenotype of obstructive HCM has been expanded to include patients with mild or no septal thickening, and how surgical management has adapted to meet this challenging anatomy
3. Demonstrate how to use stress exercise echo and post-prandial stress exercise echo to diagnose obstruction
4. Demonstrate how to use disopyramide to treat obstructive HCM and learn about novel pharmacotherapeutic approaches including myosin ATP-ase inhibition, recently approved by FDA
5. Demonstrate how to apply the new ACC/AHA 2020 guideline-based risk stratification recommendations to prevent sudden death in HCM
6. Apply strategies how to do family counseling, and complete screening and genotype analysis
7. Analyze and apply the results of genotype analysis
8. Describe why surgery is still the gold standard for obstructive HCM and how it has evolved over 5 decades
9. Recognize how atrial fibrillation impacts HCM, and apply strategies for pharmacologic treatment and long-term outcomes of atrial fibrillation ablation

TARGET AUDIENCE

Physicians, Nurse Practitioners, Physician Assistants, Cardiac Surgeons, Interventional Cardiologists, and Cardiology Fellows

ACCREDITATION

The NYU Grossman School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 
The NYU Grossman School of Medicine designates this live activity for a maximum of 14.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.